QualityDipStocks / Health Care · Biotech
BioNTech SE American Depositary Share BNTX
Outside our quality screen, so we don’t track its dips. It’s 26% below its 52-week high.
Outside our quality screen, trading well above our fair value estimate.
- Fair value est.
- $20.68−77%
- Market Value
- —
- Off 52-wk high
- −26%
- Risk vs market
- Market-likebeta 0.96
0 bullish · 5 bearish See why
Key levels
Every level vs today’s $88.17
- Fair value est.base case$20.68−76.5%
- 52-wk lowlowest close, 1 year$83.89−4.9%
- PriceFri Oct 30 close$88.17you are here
- 52-wk highhighest close, 1 year$119.34+35.4%
Fair value estimate
How the range is computed
Ten-year free-cash-flow DCF. Same 10-year free-cash-flow model as the base: discount rate 9.5% ±1 point and growth 3.0% ±2 points. Bear = 10.5% and 1.0%; bull = 8.5% and 5.0% (both fade to 3%). A model estimate from public filings, not a forecast of where the price will go.
Price is above even the bull case.
What the price implies To be worth today’s price, BNTX’s free cash flow would need to grow about 30% a year for five years; our estimate uses 3%.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 30 to Oct 30, 252 sessions). Beta = how much BNTX moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves about in line with the market, and its own price swings are 3.6× the S&P 500’s.
- Beta vs S&P 500
- 0.96
- Volatility
- 47% vs 13% SPY
- Correlation SPY
- 0.26
- Correlation QQQ
- 0.19
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 0 of 5
Nothing in our data makes a clear bull case right now.
Top bearish points 5 of 5
ValuationOur DCF fair value estimate is $20.68, 77% below the price.
ProfitabilityOperating margin narrowed to −49.0% in FY2025 from 18.1% in FY2023 (SEC filings).
Balance sheetOperating income covers interest only -98.9× over the last 12 months.
ProfitabilityLost $1.3B over the last 12 months (net income, SEC filings).
QualityDoesn’t pass our quality screen: ROE under 12% and ROIC under 10%; sales down vs the year-ago quarter.
Who’s talking about it
Notable investors, executives, analysts and public figures on BioNTech SE American Depositary Share in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 1, 9:09 PM ET.
Compare with peers
Closest in size in Biotech
All fundamentals
FCF yield 1.5% · Sales +4%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- 67.6×
- FCF yield
- 1.5%
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 6.61×
- Price / book
- n/anot reported in its SEC filings
- Market cap
- $21.3Bprice × diluted shares
- Enterprise value
- n/anot reported in its SEC filings
Growth
- Revenue, 12 months
- $3.2B
- Sales growth, 12 months
- +4.3%vs the 12 months before
- Sales growth, 3 yrs
- −45.1%/yrfrom FY2022
- Diluted EPS, 12 months
- −$4.70
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$1.3B
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- 77.6%
- Operating margin
- −49.0%
- Net margin
- −39.6%
- FCF margin
- 9.8%
- Return on equity
- n/anot reported in its SEC filings
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- n/anot reported in its SEC filings
- Total debt
- n/anot reported in its SEC filings
- Net cash
- n/acash or debt not tagged in SEC data
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- -98.9×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- $315M
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- n/ano dividend payments tagged
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- n/ano quarterly diluted share count
- Stock-based comp
- n/anot reported in its SEC filings
Trailing 12 months to Dec 31, 2025. From BioNTech SE American Depositary Share’s SEC filings, reported in EUR and converted to US dollars. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
Valuation details
DCF $20.68 · FCF value $43.30
Assumes 3.0% growth for 5 years (revenue grew -45.1% a year FY22–FY25; floored at 3%), fading to 3%; 9.5% discount rate, 3% terminal growth. FCF base $1.30 a share (fiscal year to Dec 31, 2025, converted from EUR at 1.123), from the 20-F filed Mar 10, 2026.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Momentum & 52-week range
RSI 41 · 5 days +0.1%
The business
FCF $0.4B · Sales −60%
- Free cash flow, 12 months$0.4B
- Free-cash-flow yield2.0%
- Free-cash-flow margin17%
- Gross margin76%
- Operating margin−46%
- Return on invested capital−5%
- Return on equity−9%
- Sales growth (latest quarter vs year-ago quarter)−60%
Next report
Nov 3
- DateTue Nov 3, before the open
- Consensus EPS$0.85
- Year-ago EPS($0.14)
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.
BNTX is outside our quality screen
One text when a published rule fires on one of the 333 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.